Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Guidance and Visibility -- Ignore unavailable to you. Want to Upgrade?

To: 2MAR$ who wrote (64937)	8/5/2002 8:28:06 AM
From: SusieQ1065	Read Replies (1) \| Respond to of 208838

yes...i saw that... also like the TXN call play if we get another big swoon on the SOX today/tomorrow...

To: 2MAR$ who wrote (64937)	8/5/2002 8:32:01 AM
From: 2MAR$	Respond to of 208838

Andrx Sells Certain Internet Assets To Aventis' MyDocOnline Unit, Andrx's POL Unit Signs Internet Marketing Deal With Aventis Business Editors & Health/Medical Writers FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Aug. 5, 2002--Andrx Corporation (Nasdaq:ADRX) today announced that Aventis' business unit, MyDocOnline, agreed to purchase Andrx's Dr. Chart and @Rx applications and license Andrx's patents for Internet transmission of prescriptions. Aventis also entered into a two-year marketing agreement with Andrx's Physicians' Online(TM) (POL) web portal. As part of these transactions, Andrx expects to receive approximately $6 million over the next two years. Dr. Chart is an application that allows for electronic transmission of lab results over the Internet, and @Rx is an electronic prescription writer. In connection with @Rx, Andrx granted Aventis a non-exclusive license to Andrx's U.S. patent numbers 5,737,539 and 5,845,255, related to the electronic transmission of prescriptions over the Internet. Commenting on these transactions, Richard J. Lane, Andrx's Chief Executive Officer, said: "We continue to see the value of Internet access to physicians as an element for the marketing of branded pharmaceutical products and services. Today's announcement demonstrates a major international pharmaceutical company's belief in Internet access to physicians and the value that our POL offers. Our divestiture of non-core Internet assets coupled with a marketing agreement with a major pharmaceutical player is yet another step in optimizing our Internet strategy and assets. In the interest of long term shareholder value, we will continue to evaluate our Internet assets and strategies within Andrx and its evolution toward a brand company, including evaluating additional Internet divestitures and alliances." About Andrx Andrx Corporation is a specialty pharmaceutical company engaged in the formulation and commercialization of oral controlled-release generic and brand pharmaceuticals utilizing its proprietary drug delivery technologies. Andrx also markets and distributes pharmaceutical products manufactured by third parties. This release and additional information about Andrx Corporation are also available on the Internet at: andrx.com Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this report that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, no assurance can be given as to Andrx's success in continuing to divest its Internet operations, and words such as "may," "will," "to," "expect," "plan," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative or other variations thereof or comparable terminology is intended to identify forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, including those risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. --30--jar/mi* CONTACT: Andrx Corporation, Fort Lauderdale Gale A. Blackburn Director of Investor Relations Phone: 954/217-4344 Email: gblackburn@andrx.com KEYWORD: FLORIDA INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL INTERNET PRODUCT MARKETING AGREEMENTS SOURCE: Andrx Corporation Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: businesswire.com